References
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. Internet. 2012;67:71–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20729232
- Montull B, Menéndez R, Torres A, et al. Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. PLoS One. 2016Jan 4; 11(1):e0145929.
- Menéndez R, Montull B, Reyes S, et al. Pneumonia presenting with organ dysfunctions: causative microorganisms, host factors and outcome. J Infect. 2016;73:419–426. Internet. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0163445316302043
- Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. Internet. 2004;59:960–965. cited 2018 Jun 27. Available from: http://thorax.bmj.com/cgi/doi/10.1136/thx.2003.017756
- Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–1663. Internet.
- Torres A, Menéndez R. Enterobacteriaceae and pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Eur Respir J. Internet. 2010;35:473–474. cited 2018 Jun 27. Available from: http://erj.ersjournals.com/cgi/doi/10.1183/09031936.00198109
- Prina E, Ceccato A, Torres A. New aspects in the management of pneumonia. Crit Care. Internet. 2016;20:267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27716262
- Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. Internet. 2005;171:242–248. Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.200406-808OC
- Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. Internet. 2011;15:R96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21406101
- Sibila O, Luna CM, Agustí C, et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J. Internet. 2008;32. Available from: http://erj.ersjournals.com/content/32/4/1037.long
- Nie W, Zhang Y, Cheng J, et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012;7:e47926. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23112872
- Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia. Ann Intern Med. 2015;163:519. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26258555
- Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. Internet. 2015;313:677–686. Available from.
- Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511–1518.
- Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, et al. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis. 2015;212:183–194. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25406333
- Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care. 2016;20:75. Internet. Available from: http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1230-8
- Wirz SA, Blum CA, Schuetz P, et al. Pathogen-and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J. Internet. 2016;48:984–986. cited 2016 Oct 26. Available from: http://ow.ly/xeoY302nZPx
- Ceccato A, Cilloniz C, Ranzani OT, et al. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: a post-hoc exploratory analysis of a randomized controlled trial. PLoS One. 2017;12:e0178022. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28617807
- Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12:CD007720. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29236286
- Wan Y-D, Sun T-W, Liu Z-Q, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest. 2016;149:209–219.
- Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis. 2018;66:346–354. Internet. Available from: https://academic.oup.com/cid/article/66/3/346/4110206
- Bermejo-Martin JF, Cilloniz C, Mendez R, et al. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMedicine. 2017;24:231-236.
- Bermejo-Martin J, Almansa R, Martin-Fernandez M, et al. Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. Lancet Respir Med. 2017;5(12):e35–e36.